

L Number	Hits	Search Text	DB	Time stamp
-	1524	angiogenic ADJ factor	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:41
-	23010	chimeric	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:41
-	145232	chimeric or fusion	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:41
-	9	(angiogenic ADJ factor) same chimeric	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:46
-	23013	vegf adj fusion or chimeric	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:47
-	17	vegf adj (fusion or chimeric)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:48
-	10	fgf adj (fusion or chimeric)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:48
-	46	vegf\$ adj (fusion or chimeric)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:59
-	0	vaegf-A and (vegf\$ adj (fusion or chimeric))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 10:59
-	0	vaegf-A121 and (vegf\$ adj (fusion or chimeric))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:00
-	0	vaegf-A or VEGF-A121 OR VEGF-A145 OR VEGF-A165 OR VEGF-A189 OR VEGF-A206	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:01
-	174	vegf-A or VEGF-A121 OR VEGF-A145 OR VEGF-A165 OR VEGF-A189 OR VEGF-A206	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:03
-	152	(vegf-A or VEGF-A121 OR VEGF-A145 OR VEGF-A165 OR VEGF-A189 OR VEGF-A206) AND (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:02
-	0	(vegf-A or VEGF-A121 OR VEGF-A145 OR VEGF-A165 OR VEGF-A189 OR VEGF-A206) NEAR (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:02
-	9	(vegf-A or VEGF-A121 OR VEGF-A145 OR VEGF-A165 OR VEGF-A189 OR VEGF-A206) SAME (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:03

-	218	vegf-B or VEGF-B167 OR VEGF-B186	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:22
-	205	vegf-d	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:03
-	134	vegf-E	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:03
-	1551	(ACIDIC ADJ FIBROBLAST ADJ GROWTH ADJ FACTOR) OR AFgf	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:04
-	2918	(BASIC ADJ FIBROBLAST ADJ GROWTH ADJ FACTOR) ORBFgf	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:05
-	540007	ANGIOPOIETIN-1 OF ang1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:05
-	13	vegf-d SAME (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:05
-	5	vegf-E SAME (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:06
-	50	((ACIDIC ADJ FIBROBLAST ADJ GROWTH ADJ FACTOR) OR AFgf) SAME (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:06
-	70	((BASIC ADJ FIBROBLAST ADJ GROWTH ADJ FACTOR) ORBFgf) SAME (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:06
-	13	(ANGIOPOIETIN-1 OF ang1) SAME (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:06
-	12	(vegf-B or VEGF-B167 OR VEGF-B186) SAME (chimeric or fusion)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:07
-	6	VEGF-B167	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/01/08 11:23

were significantly less necrotic, suggesting that necrosis in these tumors is the result of insufficient angiogenesis.

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:777911 CAPLUS
DOCUMENT NUMBER: 128:71142
TITLE: Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate
AUTHOR(S): Olson, Timothy A.; Mohanraj, D.; Roy, Sabita; Ramakrishnan, S.
CORPORATE SOURCE: Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA
SOURCE: International Journal of Cancer (1997), 73(6), 865-870
CODEN: IJCNW; ISSN: 0020-7136
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Tumor-derived vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) plays an important role in neovascularization and the development of tumor stroma. Furthermore, VEGF receptors are over-expressed in the endothelial cells of tumor vasculature and almost non-detectable in the vascular endothelium of adjoining normal tissues. The differential expression of receptor offers a selective advantage for targeting cytotoxic toxin polypeptides. We have prepd. a vascular targeting reagent by chem. linking recombinant VEGF to a truncated form of diphtheria toxin. The VEGF-toxin conjugate was selectively toxic to endothelial cell lines and inhibited exptl. neovascularization of the chick chorioallantoic membrane. In the present study, we examd. the effects of VEGF-toxin conjugate on solid tumor growth. Athymic nude mice with established s.c. tumors were treated with daily i.p. injections of the VEGF-toxin conjugate or free toxin. When compared with control animals treated with the toxin polypeptide alone, the conjugate-treated animals displayed a significant inhibition of tumor growth. Histol. anal. of tumors from conjugate-treated animals revealed hemorrhagic necrosis consistent with a vascular-mediated injury. In contrast, highly vascularized normal tissues from conjugate-treated animals demonstrated no evidence of hemorrhage or tissue injury. The conjugate was well tolerated without apparent toxicities. Our results illustrate the anti-tumor activity of a VEGF-toxin conjugate selectively targeting the tumor neovasculature.

L9 ANSWER 3 OF 3 PCTFULL COPYRIGHT 2003 Univention
**** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER
**** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

=> d his

(FILE 'HOME' ENTERED AT 16:59:28 ON 08 JAN 2003)

FILE 'MEDLINE' ENTERED AT 16:59:40 ON 08 JAN 2003

L1 6036 S VEGF?
L2 102848 S FUSION
L3 59 S L1 (S) L2
L4 220976 S TARGET?
L5 126030 S ENDOTHELI?
L6 14 S L1 (S) L2 (S) L4 (S) L5

FILE 'BIOSIS, EMBASE, SCISEARCH, CAPLUS, PCTFULL' ENTERED AT 17:05:43 ON 08 JAN 2003

L7 86 S L6
L8 59 DUP REM L7 (27 DUPLICATES REMOVED)
L9 3 S L8 NOT PY>1998

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
17.86	24.81

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.65	-0.65

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 17:09:24 ON 08 JAN 2003

transgeniques exprimant ces
 proteines et des analogues fonctionnellement equivalents de ces
 proteines. L'invention cerne
 enfin des methodes permettant d'induire la differenciation de
 motoneurones somatiques et de traiter
 des maladies liees a la carence en motoneurones fonctionnant
 normalement, des maladies
 neurodegeneratives, des troubles neurologiques et des maladies
 neuromusculaires.

L17 ANSWER 5 OF 5 MEDLINE DUPLICATE 2
 ACCESSION NUMBER: 95403738 MEDLINE
 DOCUMENT NUMBER: 95403738 PubMed ID: 7673487
 TITLE: Transplanted human neurons derived from a teratocarcinoma
 cell line (NTera-2) mature, integrate, and survive for over
 1 year in the nude mouse brain.
 AUTHOR: Kleppner S R; Robinson K A; Trojanowski J Q; Lee V M
 CORPORATE SOURCE: Department of Pathology and Laboratory Medicine, University
 of Pennsylvania Medical School, Philadelphia 19104, USA.
 SOURCE: JOURNAL OF COMPARATIVE NEUROLOGY, (1995 Jul 10) 357 (4)
 618-32.
 Journal code: 0406041. ISSN: 0021-9967.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199510
 ENTRY DATE: Entered STN: 19951026
 Last Updated on STN: 19970203
 Entered Medline: 19951019

AB Retinoic acid (RA) induces a human teratocarcinoma cell line (NTera-2 or
 NT2) to give rise exclusively to ***post*** - ***mitotic***
 neuron -like (NT2N) cells, but NT2N cells never acquire a fully
 mature neuronal phenotype in vitro. To determine whether NT2N cells can
 mature into adult neuron-like cells in vivo, purified NT2N cells were
 grafted into different regions of the central nervous system (CNS) of
 adult and neonatal athymic mice, and the grafts were examined
 immunohistochemically by light, confocal, and electron microscopy using
 antibodies to a panel of developmentally regulated neuronal polypeptides.
 NT2N grafts were distinguished from endogenous mouse neurons with
 antibodies that recognize human or murine specific epitopes in selected
 neuronal polypeptides. Viable NT2N cells were identified in > 89% of graft
 recipients (N = 90), and some grafts survived 14 months. Within 3 weeks of
 implantation, grafted NT2N cells re-extended their processes, and
 the location of the grafts (e.g., septum versus neocortex) appeared to
 determine the extent to which processes were elaborated. Within the early
 post-transplantation period, grafted NT2N cells expressed the same
 neuronal polypeptides as their in vitro counterparts. However, between 6
 weeks and 4-6 months post- ***implantation***, the grafted NT2N cells
 progressively acquired the molecular phenotype of fully mature in vivo
 neurons as evidenced by dramatically increased expression of the most
 highly phosphorylated isoforms of the heavy neurofilament subunit, and the
 de novo expression of adult CNS tau. Notably, the time course for the
 extension of processes and the expression of neuronal polypeptides by NT2N
 grafts was similar in neonatal and adult mice. Although grafted NT2N cells
 formed synapse-like structures and elaborated dendrites and axons, these
 axons remained unmyelinated. Finally, none of the transplanted NT2N cells
 reverted to a neoplastic state. These studies demonstrate that pure
 populations of grafted human NT2N cells acquire a fully mature neuronal
 phenotype in vivo, and that these cells integrate and survive for > 1 year
 post- ***implantation*** in the mouse CNS. These human neuron-like
 cells are an attractive model system for studies of neuronal development,
 polarity and transplantation.

=> d his

(FILE 'HOME' ENTERED AT 09:52:39 ON 08 JAN 2003)

FILE 'MEDLINE' ENTERED AT 09:52:45 ON 08 JAN 2003

L1 3 S POST-MITOTIC HUMAN NEURON
 L2 108 S POST-MITOTIC NEURON
 L3 157887 S IMPLANT?
 L4 0 S L1 (S) L3
 L5 2 S L2 (S) L3
 L6 1484089 S TREATMENT
 L7 1819680 S TREAT?

```

L8      68237 S ALZHEIMERS DISEASE OR PARKINSONS DISEASE OR HUNTINGTONS DISEA
L9      123638 S ALZHEIMER? DISEASE OR PARKINSON? DISEASE OR HUNTINGTON? DISEA
L10     229826 S POST-MITOTIC URON OR NEURON
L11     344762 S REVIEW
L12      171 S L3 (S) L6 (S) L9
L13      13 S L3 (S) L6 (S) L9 (S) L11
L14       0 S L3 (S) L6 (S) L9 (S) L11 (S) L10
L15       8 S L3 (S) L6 (S) L11 (S) L10

```

FILE 'PCTFULL, USPATFULL, MEDLINE, BIOSIS, EMBASE, CAPLUS, CONFSCI,
SCISEARCH' ENTERED AT 10:17:36 ON 08 JAN 2003

```

L16      9 S L5
L17      5 DUP REM L16 (4 DUPLICATES REMOVED)

```

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
18.50	39.12

FULL ESTIMATED COST

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 10:20:47 ON 08 JAN 2003

Connecting via winsock to STN

Welcome to STN International! Enter x:X

LOGINID:sssptal632rrs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

```

NEWS 1      Web Page URLs for STN Seminar Schedule - N. America
NEWS 2  Apr 08 "Ask CAS" for self-help around the clock
NEWS 3  Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4  Apr 09 ZDB will be removed from STN
NEWS 5  Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6  Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7  Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8  Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9  Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
              saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
              now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 27 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28 Oct 21 EVENTLINE has been reloaded
NEWS 29 Oct 24 BEILSTEIN adds new search fields
NEWS 30 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 31 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 32 Nov 18 DKILIT has been renamed APOLLIT
NEWS 33 Nov 25 More calculated properties added to REGISTRY
NEWS 34 Dec 02 TIBKAT will be removed from STN
NEWS 35 Dec 04 CSA files on STN
NEWS 36 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 37 Dec 17 TOXCENTER enhanced with additional content
NEWS 38 Dec 17 Adis Clinical Trials Insight now available on STN

```